Upload Image (Max 20MB per Image)
Proteonomix, a biotechnology company, has announced Institutional Review Board (IRB) approval for its clinical trial of UMK-121 in patients with end stage liver disease. The company previously signed an agreement with the University of ...
Tags: clinical trial, drug therapy, UMK-121 technology